HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

Status:
RECRUITING

Trial end date:
2026-12-15

Target enrollment:

Participant gender:

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

PHASE1

HCW Biologics